Literature DB >> 12595757

Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells.

Chuen-Mao Yang1, Chin-Sung Chien, Yuun-Hwa Ma, Li-Der Hsiao, Ching-Hsuan Lin, Chou- Bing Wu.   

Abstract

It has been suggested that bradykinin (BK) plays an important role in regulating neointimal formation after vascular injury. However, implication of BK in the growth of rat vascular smooth muscle cells (VSMCs) is controversial. Therefore, we examined the mitogenic effect of BK on VSMCs associated with activation of mitogen-activated protein kinase (MAPK). Both [(3)H]thymidine incorporation and p42/p44 MAPK phosphorylation were activated by BK in time- and concentration-dependent manners. Pretreatment of these cells with neither pertussis toxin nor cholera toxin attenuated the BK-induced responses. Pretreatment of VSMCs with Hoe 140 (a selective B(2) receptor antagonist), U73122 (an inhibitor of phospholipase C), and BAPTA/AM (an intracellular Ca(2+) chelator) inhibited both [(3)H]thymidine incorporation and p42/p44 MAPK phosphorylation in response to BK. BK-induced [(3)H]thymidine incorporation and p42/p44 MAPK phosphorylation were inhibited by pretreatment of VSMCs with tyrosine kinase inhibitors (genistein and herbimycin A), protein kinase C (PKC) inhibitors (staurosporine, Go-6976, and Ro-318220), an MAPK kinase inhibitor (PD98059), and a p38 MAPK inhibitor (SB203580). Overexpression of the dominant negative mutants, H-Ras-15A and Raf-N4, suppressed p42/p44 MAPK activation induced by BK and PDGF-BB, indicating that Ras and Raf may be required for activation of these kinases. From these results, we concluded that the mitogenic effect of BK is mediated through activation of the Ras/Raf/MEK/MAPK pathway similar to that of PDGF-BB. BK-mediated MAPK activation was modulated by Ca(2+), PKC, and tyrosine kinase all of which are associated with cell proliferation in rat cultured VSMCs. Copyright 2003 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595757     DOI: 10.1007/bf02256056

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  7 in total

1.  The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin.

Authors:  Ch Golias; A Charalabopoulos; D Stagikas; K Charalabopoulos; A Batistatou
Journal:  Hippokratia       Date:  2007-07       Impact factor: 0.471

2.  Evidence for prostacyclin and cAMP upregulation by bradykinin and insulin-like growth factor 1 in vascular smooth muscle cells.

Authors:  Jerry G Webb; Yan Tan; Miran A Jaffa; Ayad A Jaffa
Journal:  J Recept Signal Transduct Res       Date:  2010-04       Impact factor: 2.092

3.  Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor.

Authors:  Juan C Osorio; Faisal H Cheema; Timothy P Martens; Naila Mahmut; Caroline Kinnear; Ana M D Gonzalez; William Bonney; Shunichi Homma; James K Liao; Seema Mital
Journal:  Can J Physiol Pharmacol       Date:  2008-09       Impact factor: 2.273

4.  Anti-inflammatory mechanism of polyunsaturated fatty acids in Helicobacter pylori-infected gastric epithelial cells.

Authors:  Sun Eun Lee; Joo Weon Lim; Jung Mogg Kim; Hyeyoung Kim
Journal:  Mediators Inflamm       Date:  2014-06-02       Impact factor: 4.711

5.  Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma.

Authors:  Yari Ciribilli; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-10-23

6.  Bradykinin-mediated Ca2+ signalling regulates cell growth and mobility in human cardiac c-Kit+ progenitor cells.

Authors:  Gang Li; Hui Che; Wei-Yin Wu; Ling-Jun Jie; Guo-Sheng Xiao; Yan Wang; Gui-Rong Li
Journal:  J Cell Mol Med       Date:  2018-08-17       Impact factor: 5.310

Review 7.  MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis.

Authors:  Erna Marija Meškytė; Sabiha Keskas; Yari Ciribilli
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.